RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vifor Pharma Stock

Vifor Pharma P/S 2024

Vifor Pharma P/S

4.46

Ticker

VIFN.SW

ISIN

CH0364749348

WKN

A2DRZ4

As of Dec 6, 2024, Vifor Pharma's P/S ratio stood at 4.46, a 0% change from the 0 P/S ratio recorded in the previous year.

The Vifor Pharma P/S history

Vifor Pharma Aktienanalyse

What does Vifor Pharma do?

Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Vifor Pharma's P/S Ratio

Vifor Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Vifor Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Vifor Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Vifor Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Vifor Pharma stock

What is the price-to-earnings ratio of Vifor Pharma?

The price-earnings ratio of Vifor Pharma is currently 4.46.

How has the price-earnings ratio of Vifor Pharma changed compared to last year?

The price-to-earnings ratio of Vifor Pharma has increased by 0% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Vifor Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Vifor Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Vifor Pharma affect the company?

An increase in the price-earnings ratio of Vifor Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Vifor Pharma affect the company?

A decrease in the price-earnings ratio of Vifor Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Vifor Pharma?

Some factors that influence the price-earnings ratio of Vifor Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Vifor Pharma pay?

Over the past 12 months, Vifor Pharma paid a dividend of 2 CHF . This corresponds to a dividend yield of about 1.2 %. For the coming 12 months, Vifor Pharma is expected to pay a dividend of 6.28 CHF.

What is the dividend yield of Vifor Pharma?

The current dividend yield of Vifor Pharma is 1.2 %.

When does Vifor Pharma pay dividends?

Vifor Pharma pays a quarterly dividend. This is distributed in the months of June, June, June, May.

How secure is the dividend of Vifor Pharma?

Vifor Pharma paid dividends every year for the past 24 years.

What is the dividend of Vifor Pharma?

For the upcoming 12 months, dividends amounting to 6.28 CHF are expected. This corresponds to a dividend yield of 3.78 %.

In which sector is Vifor Pharma located?

Vifor Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vifor Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vifor Pharma from 5/3/2022 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 4/29/2022.

When did Vifor Pharma pay the last dividend?

The last dividend was paid out on 5/3/2022.

What was the dividend of Vifor Pharma in the year 2023?

In the year 2023, Vifor Pharma distributed 2 CHF as dividends.

In which currency does Vifor Pharma pay out the dividend?

The dividends of Vifor Pharma are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vifor Pharma

Our stock analysis for Vifor Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.